Pharmacovigilance challenges in Biosimilars


Same proportion pharmacovigilance for biosimilars has comparatively more different from other products. Biosimilars 2019 session mainly look that have already been announced to incorporate enhanced tracking and follow-up of post marketing surveillance issues, and on FDA initiative planned different changes in AERS, pilots of latest developed post market strategies of drug-monitoring and ADR related problems. the rules of biosimilars for pharmacovigilance and pharma epidemiology are the points that shall be laid emphasis within the session In USA average annual income mostly spend on biologics comparing to generic drugs for example:16% on biologics and three on other drugs.


  • Manufacturing methods
  • Product names
  • Generics and brand name products
  • Postapproval surveillance for immunogenicity
  • Evolving guidelines

Related Conference of Pharmacovigilance challenges in Biosimilars

December 05-06, 2023

2nd World Congress on Precision and Personalized Medicine

Zurich, Switzerland
February 01-02, 2024

37th World Congress on Pharmacology

Dubai, UAE
February 22-23, 2024

34th Annual European Pharma Congress

Zurich, Switzerland
April 04-05, 2024

17th European Biosimilars Congress

Madrid, Spain
April 11-12, 2024

5th Annual Congress on Antibiotics and Bacterial Infections

Amsterdam, Netherlands
May 09-10, 2024

4th Global Summit on Pharmaceutical Research

Barcelona, Spain
May 16-17, 2024

18th World Drug Delivery Summit

Rome, Italy
May 30-31, 2024

9th Pharmaceutical Chemistry Conference

Paris, France
September 11-12, 2024

9th International Conference on Future Pharma and Innovations

Amsterdam, Netherlands
September 25-26, 2024

4th World Congress on Rare Diseases & Orphan Drugs

Paris, France

Pharmacovigilance challenges in Biosimilars Conference Speakers

    Recommended Sessions

    Related Journals

    Are you interested in